http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107496921-A
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_49f0920dbf4baf180654f61d90d77ff5 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
filingDate | 2017-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73bc6b966a144eff471e7845e797842c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d601c8c1a56bf747e06856f76d3860f7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6b48ab6b2aa7b997066266041030202 |
publicationDate | 2017-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-107496921-A |
titleOfInvention | Sema3E/PlexinD1 signal paths target drug is preparing the application in suppressing Neointimal formation medicine |
abstract | The invention discloses using application of the Sema3E/PlexinD1 signal paths as the medicine of target spot in the medicine for suppressing Neointimal formation is prepared, it is found by the applicant that Sema3E/PlexinD1 signal paths, which can act on smooth muscle cell, suppresses its proliferation apoptosis, on the one hand by suppressing endothelial cell platelet derived growth factor(PDGF)Generation, on the other hand by activating Sema3E/PlexinD1 downstream signaling pathways, double action significantly inhibits smooth muscle cell proliferation migration so as to suppress Neointimal formation, and new thinking is provided for vascular proliferative diseases such as atherosclerosis, the postoperative ISRs of stenter to implant. |
priorityDate | 2017-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 27.